Second Opinion:
Proceedings from an Interactive Case-Based Symposium on the Management of Patients with Early and Advanced Breast Cancer

Select Publications

Eric P Winer, MD

Baselga J et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S3-3.


Hurvitz SA et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label Phase II study (TDM4450g/BO21976). European Multidisciplinary Cancer Congress 2011;Abstract 5001.


Julie R Gralow, MD


**George W Sledge Jr, MD**


**Hope S Rugo, MD**


Baselga J et al. Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: Results of the BOLERO-2 Phase III trial. *European Multidisciplinary Cancer Congress* 2011;Abstract 9LBA.


Bourgier C et al. Exploratory subgroup analysis of the TAMRAD Phase 2 GINECO trial comparing tamoxifen (TAM) plus everolimus (RAD) with TAM alone in patients with hormone-receptor–positive, HER2-negative metastatic breast cancer (mBC) with prior exposure to aromatase inhibitors (AIs): Implication for research strategies. *European Multidisciplinary Cancer Congress* 2011;Abstract 5005.


Mayer IA et al. Phase II trial of RAD001 (everolimus), an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). *San Antonio Breast Cancer Symposium* 2011;Abstract PD09-06.


Yardley DA et al. *Results of ENCORE 301, a randomized, Phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI)*. Breast Cancer Symposium 2011;Abstract 268.

**Ian E Smith, MD**


Gianni L et al. *Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (‘NeoSphere’)*. San Antonio Breast Cancer Symposium 2010;Abstract S3-2.


Jones S et al. *Phase II trial of adjuvant TC (docetaxel/cyclophosphamide) plus trastuzumab (HER TC) in HER2 positive early stage breast cancer patients*. San Antonio Breast Cancer Symposium 2011;Abstract PD07-03.


